InvestorsHub Logo
Followers 50
Posts 9090
Boards Moderated 1
Alias Born 01/13/2007

Re: Plummy Potter post# 20819

Thursday, 12/01/2022 9:09:45 PM

Thursday, December 01, 2022 9:09:45 PM

Post# of 21544
There are several issues now that I look and I'm sure more will come out. I still think it shows a positive trend towards running an additional trial. I always figured once data was out folks would still be guessing and seems we are. I think they may be hiding one of their primary endpoints (ADCS-ADL) but I could be wrong based on the murky language in the PR. Stat significance certainly isn't huge either but I'm sure we would take it. Just not something likely to be able to avoid a pivotal P3 trial IMO. My take is its essentially a 45% slowing of the decline. Hopefully good for patients but not hugely exciting as a disease modification. JMHO
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SNPX News